Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside

An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer

(2009) M. Schmidt et al.   ANNALS OF ONCOLOGY

EpCAM: Another Surface-to-Nucleus Missile

(2009) Graham Carpenter et al.   CANCER CELL

Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer

(2009) Muhammad Wasif Saif et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The Emerging Role of EpCAM in Cancer and Stem Cell Signaling

(2009) M. Munz et al.   CANCER RESEARCH

Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues

(2009) Thoralf Christoffersen et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Adjuvant Therapy With the Monoclonal Antibody Edrecolomab Plus Fluorouracil-Based Therapy Does Not Improve Overall Survival of Patients With Stage III Colon Cancer

(2009) Anthony L.A. Fields et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

(2009) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased Susceptibility to Immune Destruction of B16BL6 Tumor Cells Engineered to Express a Novel Pro-Smac Fusion Protein

(2009) Dominik Rüttinger et al.   JOURNAL OF IMMUNOTHERAPY

Nuclear signalling by tumour-associated antigen EpCAM

(2009) Dorothea Maetzel et al.   NATURE CELL BIOLOGY